The Melanoma Letter Summer 2013, Vol. 31, No. 2

In this issue of The Melanoma Letter, Dr. Caroline Robert and colleagues discuss exciting ongoing trials with new MEK inhibitors designed to increase the extent and durability of responses and mitigate the risk of carcinogenesis. The recent approval of trametinib (MekinistTM) was the first salvo fired for MEK inhibition in melanoma management, and many other MEK therapies are being tested.